IHS FormWeb
Approved Formulary
Search by name
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
IHS FormWeb
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Search results for:
sarilumab
sarilumab
Restricted Medications
Non Formulary
Brand names:
Kevzara
Form
Strength
INJECTION, INTRAVENOUS
200 mg
Display
Disease-Modifying Antirheumatic Drugs
Class:
923600
Medication comments:
sarilumab (Kevzara) is the alternative agent to
tocilizumab (Actemra)
in the setting of COVID-19.
Last updated:
Dec. 7, 2021
Look-Alike/Sound-Alike
sarilumab confused with adalimumab, certolizumab pegol, golimumab, siltuximab, tocilizumab
UpToDate
FDA DailyMed Package Insert
MedLinePlus (Patient Information)
MSDS Online